Corium International Inc. (CORI) Trading Up 10.9%
Corium International Inc. (NASDAQ:CORI) shares were up 10.9% during trading on Thursday . The company traded as high as $8.33 and last traded at $7.11, with a volume of 354,258 shares traded. The stock had previously closed at $6.41.
A number of research analysts have recently commented on CORI shares. FBR & Co reissued a “buy” rating on shares of Corium International in a research report on Thursday, June 16th. Leerink Swann reissued a “buy” rating and set a $14.00 target price on shares of Corium International in a research report on Wednesday, May 18th. Jefferies Group reissued a “buy” rating and set a $9.00 target price on shares of Corium International in a research report on Wednesday, May 11th. Zacks Investment Research raised shares of Corium International from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Tuesday, July 19th. Finally, Needham & Company LLC reissued a “buy” rating and set a $15.00 target price on shares of Corium International in a research report on Thursday, June 23rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Corium International currently has a consensus rating of “Buy” and an average price target of $11.92.
The company’s market cap is $138.40 million. The stock’s 50 day moving average is $4.67 and its 200-day moving average is $4.37.
Corium International (NASDAQ:CORI) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. Equities analysts predict that Corium International Inc. will post ($1.63) EPS for the current fiscal year.
Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.